Oncoplastic Breast-conserving Surgery in Non-metastatic Breast Cancer Patients

• Status: Withdrawn
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

Breast-conserving surgery (BCS) is the traditional surgical treatment for early-stage breast cancer patients. There are evidences indicating that oncoplastic-BCS (displacement technique) could improve cosmetic outcomes and/or quality of life, and has similar oncological safety as traditional BCS does. However, there are no prospective trial comparing oncoplastic-BCS vs. traditional BCS in terms of cosmetic outcomes and oncological safety. In this study, the investigators are going to address this issue by assigning patients into traditional and oncoplastic-BCS group, based on their preference.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
• Treatments: Trastuzumab

Criteria

Inclusion Criteria:

• Informed consent signed

• ECOG<=2

• Non-metastatic breast cancer patients with unilateral breast cancer confirmed by pathology.

• Operable or operable after neoadjuvant chemotherapy.

• Extensive, diffuse micro-calcifications on mammography before surgery

• No history of breast surgery or breast radiation therapy before.

• Able to follow the standard of care in adjuvant chemotherapy, radiation therapy, endocrine therapy and targeted therapy after surgery.

Exclusion Criteria:

• Multifocal/multicentric diseases noticed before surgery.

• Inflammatory breast cancer or invasive micro-papillary carcinoma of the breast confirmed by pathology before surgery.

• Tumor size > 5 cm revealed by physical examination, Ultrasound or mammography before surgery.

• Tumor size/breast size ratio >0.5 revealed by by physical examination, Ultrasound or mammography before surgery.

• Have other malignant tumors.

• Have severe co-morbidities that compromise the patients' compliance to our protocol, or endanger the patients.

• Participated in other clinical trials.

• Pathologically confirmed metastatic breast cancer, bilateral breast cancer or DCIS patients.

• Patients with any organ failure.

• Pregnancy women

• Patients who desire to have mastectomy before surgery.